Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Glympse Bio is a biotechnology company at the forefront of developing a novel, tunable biosensor platform. Their technology aims to revolutionize disease detection and monitoring by non-invasively measuring protease activity directly in the body, which is a key indicator of disease. These activity-based biosensors are designed to provide real-time insights into disease progression and treatment response across a range of conditions, including oncology, fibrosis (like NASH), and immunology. By enabling earlier and more accurate diagnoses, Glympse Bio seeks to improve patient outcomes and facilitate personalized medicine.
The Cambridge headquarters serves as the primary center for Glympse Bio's research and development, clinical operations, strategic partnerships, and corporate administration.
Situated in the Kendall Square area, the facility likely includes state-of-the-art laboratories for biosensor development and testing, alongside modern office spaces designed to foster collaboration and innovation.
The work culture at Glympse Bio's headquarters is expected to be dynamic, science-driven, and mission-focused, emphasizing collaboration, cutting-edge research, and a commitment to tackling significant healthcare challenges. Employees likely share a passion for translational medicine and patient impact.
Its location in Kendall Square provides Glympse Bio with unparalleled access to a rich ecosystem of academic institutions (like MIT and Harvard), research organizations, venture capital, and a highly skilled talent pool, crucial for a pioneering biotech company.
While Glympse Bio's physical operations are centered in the United States (Cambridge, MA), its scientific collaborations, potential clinical trial sites, and the ultimate application of its diagnostic technologies are global in scope. The company engages with international researchers and institutions and aims to address diseases that affect populations worldwide. Its investor base also includes international entities, indicating a global interest and reach.
245 First Street, Suite 1800
Cambridge
MA
USA
Address: N/A
N/A
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Glympse Bio' leadership includes:
Glympse Bio has been backed by several prominent investors over the years, including:
Glympse Bio has maintained a relatively stable core executive team recently, with key appointments made just outside the strict 12-month window bolstering its clinical and strategic leadership. No major C-suite departures have been publicly announced in the immediate past year.
Discover the tools Glympse Bio uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Glympse Bio likely utilizes common corporate email formats. The most probable patterns involve combinations of first name, last name, and first initial.
[first_initial][last]@glympsebio.com (e.g., jdoe@glympsebio.com) or [first].[last]@glympsebio.com (e.g., jane.doe@glympsebio.com)
Format
cl Loew@glympsebio.com (example using first initial last name format for CEO)
Example
80%
Success rate
Glympse Bio Press Release • January 9, 2023
Glympse Bio announced the appointment of Jorge DiMartino, M.D., Ph.D., as Chief Medical Officer. Dr. DiMartino will lead the company's clinical strategy and development of its novel biosensor platform for non-invasive disease monitoring....more
Glympse Bio Press Release • November 1, 2022
Glympse Bio announced the appointment of Wendy Winckler, Ph.D., as Chief Scientific Officer. Dr. Winckler will lead the company’s research organization and oversee discovery and translational research for its pipeline of programs in oncology, fibrosis and infectious diseases....more
Glympse Bio Press Release • May 10, 2022
Glympse Bio announced that the first patient has been dosed in its Phase 1 clinical study evaluating the safety, tolerability and pharmacokinetics of its injectable biosensors for monitoring treatment response in cancer patients....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Glympse Bio, are just a search away.